Previous close | 46.18 |
Open | 45.79 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 45.46 - 45.88 |
52-week range | 45.46 - 66.00 |
Volume | |
Avg. volume | 88,583 |
Market cap | 34.554B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 28.02 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.39 (0.85%) |
Ex-dividend date | 09 May 2023 |
1y target est | N/A |
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.